<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LEPIRUDIN <img border="0" src="../images/pr.gif"/></span><br/>(le-pir'u-din)<br/><span class="topboxtradename">Refludan<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">direct thrombin inhibitor</span>; <span class="classification">anticoagulant</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Highly specific direct inhibitor of thrombin. One molecule of lepirudin binds to one molecule of thrombin and thereby blocks
         the thrombogenic activity of thrombin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Increases PT/INR and aPTT values in relation to the dose given. Effectiveness is indicated by aPTT ratio in target range of
         1.5 to 2.5.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Anticoagulation in patients with heparin-induced thrombocytopenia (HIT).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to lepirudin; lactation; pregnancy (category B); intracranial bleeding; patients with increased risk of bleeding
         (e.g., recent surgery, CVA, advanced kidney impairment). Safety and efficacy in children not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Serious liver injury (e.g., cirrhosis); concomitant administration with streptokinase; renal impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Anticoagulation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.4 mg/kg initial bolus (max: 44 mg) followed by 0.15 mg/kg/h (max: 16.5 mg/h) for 210 d, adjust rate to maintain aPTT
               of 1.52.5<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute by adding 1 mL of sterile water for injection or NS to the 50-mg vial. To prepare bolus dose, withdraw reconstituted
                  solution into a 10-cc syringe and dilute to 10 mL with sterile water for injection, NS or D5W to yield 5 mg/mL.  <span class="methodtype">Continuous:</span> Transfer the contents of two reconstituted vials into 250 or 500 mL of D5W or NS to yield of 0.4 or 0.2 mg/mL, respectively.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span>  Give over 1520 sec.  <span class="methodtype">Continuous:</span> Give at a rate determined by body weight.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Diluted solution is stable for 24 h during infusion. Store unopened vials at 2°25° C (36°77°
            F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CNS:</span>
<span class="speceff-life">Intracranial bleeding</span>. <span class="typehead">CV:</span> Heart failure, ventricular fibrillation, pericardial effusion, <span class="speceff-life">MI</span>. <span class="typehead">GI:</span> Abnormal LFTs. <span class="typehead">Hematologic:</span> Bleeding from injection site, anemia, hematoma, bleeding, hematuria, GI and rectal bleeding, epistaxis, hemothorax, vaginal
      bleeding. <span class="typehead">Respiratory:</span> Pneumonia, cough, bronchospasm, stridor, dyspnea. <span class="typehead">Skin:</span> Allergic skin reactions. <span class="typehead">Body as a Whole:</span> Sepsis, abnormal kidney function, multiorgan failure. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b>Warfarin,</b>
<span class="classification">nsaids</span>, <span class="classification">salicylates</span>, <span class="classification">antiplatelet agents</span> increases risk of bleeding. <span class="typehead">Herbal:</span>
<b>Feverfew,</b>
<b>ginkgo,</b>
<b>ginger,</b>
<b>valerian</b> may potentiate bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Distributed primarily to extracellular compartment. <span class="typehead">Metabolism:</span> Metabolized by catabolic hydrolysis in serum. <span class="typehead">Elimination:</span> 48% excreted in urine. <span class="typehead">Half-Life:</span> 1.3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline PT/INR and aPTT prior to initiation of therapy (withhold therapy and notify physician if baseline aPTT
            ratio <img src="../images/special/greaterorequal.gif"/>2.5); aPTT 4 h after start of therapy and at least once daily (more
            often with renal or hepatic impairment) thereafter.
         </li>
<li>Give with extreme caution to those at increased risk for bleeding.</li>
<li>Monitor carefully for bleeding events (e.g., from puncture wounds, hematoma, hematuria); and report immediately.</li>
<li>Do not give oral anticoagulants until lepirudin dose has been reduced and aPTT ratio lowered to just above 1.5.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>